Works matching IS 22351795 AND DT 2022 AND VI 11 AND IP 1

Results: 9

Front & Back Matter.

Published in:: Liver Cancer (2235-1795), 2022, v. 11, n. 1, p. 1, doi. 10.1159/000522097
Publication type:: Article

Newly Developed Modified ALBI Grade Shows Better Prognostic and Predictive Value for Hepatocellular Carcinoma.

Published in:

2022

By:

Kudo, Masatoshi

Publication type:

Editorial

First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials.

Published in:

Liver Cancer (2235-1795), 2022, v. 11, n. 1, p. 75, doi. 10.1159/000520278

By:

Cabibbo, Giuseppe;
Reig, Maria;
Celsa, Ciro;
Torres, Ferran;
Battaglia, Salvatore;
Enea, Marco;
Rizzo, Giacomo Emanuele Maria;
Petta, Salvatore;
Calvaruso, Vincenza;
Di Marco, Vito;
Craxì, Antonio;
Singal, Amit G.;
Bruix, Jordi;
Cammà, Calogero

Publication type:

Article

Efficacy and Safety of 4 Fractions of Carbon-Ion Radiation Therapy for Hepatocellular Carcinoma: A Prospective Study.

Published in:

Liver Cancer (2235-1795), 2022, v. 11, n. 1, p. 61, doi. 10.1159/000520277

By:

Shibuya, Kei;
Katoh, Hiroyuki;
Koyama, Yoshinori;
Shiba, Shintaro;
Okamoto, Masahiko;
Okazaki, Shohei;
Araki, Kenichiro;
Kakizaki, Satoru;
Shirabe, Ken;
Ohno, Tatsuya

Publication type:

Article

Evolution of Survival Impact of Molecular Target Agents in Patients with Advanced Hepatocellular Carcinoma.

Published in:

Liver Cancer (2235-1795), 2022, v. 11, n. 1, p. 48, doi. 10.1159/000519868

By:

Kobayashi, Kazufumi;
Ogasawara, Sadahisa;
Takahashi, Aya;
Seko, Yuya;
Unozawa, Hidemi;
Sato, Rui;
Watanabe, Shunji;
Moriguchi, Michihisa;
Morimoto, Naoki;
Tsuchiya, Satoshi;
Iwai, Kenji;
Inoue, Masanori;
Ogawa, Keita;
Ishino, Takamasa;
Iwanaga, Terunao;
Sakuma, Takafumi;
Fujita, Naoto;
Kanzaki, Hiroaki;
Koroki, Keisuke;
Nakamura, Masato

Publication type:

Article

APPLE News.

Published in:: 2022
Publication type:: Proceeding

Tenofovir Is Superior to Entecavir on Tertiary Prevention for BCLC Stage 0/A Hepatocellular Carcinoma after Curative Resection.

Published in:

Liver Cancer (2235-1795), 2022, v. 11, n. 1, p. 22, doi. 10.1159/000518940

By:

Tsai, Ming-Chao;
Wang, Chih-Chi;
Lee, Wei-Chen;
Lin, Chih-Che;
Chang, Kuo-Chin;
Chen, Chien-Hung;
Hung, Chao-Hung;
Lin, Ming-Tsung;
Hsiao, Chang-Chun;
Chen, Chao-Long;
Chien, Rong-Nan;
Hu, Tsung-Hui

Publication type:

Article

Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma.

Published in:

Liver Cancer (2235-1795), 2022, v. 11, n. 1, p. 9, doi. 10.1159/000518619

By:

Ng, Kennedy Yao Yi;
Tan, Sze Huey;
Tan, Jack Jie En;
Tay, Desiree Shu Hui;
Lee, Ailica Wan Xin;
Ang, Andrea Jing Shi;
Wong, Lawrence Wen Jun;
Choo, Su Pin;
Tai, David Wai-Meng;
Lee, Joycelyn Jie Xin

Publication type:

Article

Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma.

Published in:

Liver Cancer (2235-1795), 2022, v. 11, n. 1, p. 38, doi. 10.1159/000519867

By:

Rimassa, Lorenza;
Kelley, Robin Kate;
Meyer, Tim;
Ryoo, Baek-Yeol;
Merle, Philippe;
Park, Joong-Won;
Blanc, Jean-Frederic;
Lim, Ho Yeong;
Tran, Albert;
Chan, Yi-Wah;
McAdam, Paul;
Wang, Evelyn;
Cheng, Ann-Lii;
El-Khoueiry, Anthony B.;
Abou-Alfa, Ghassan K.

Publication type:

Article